Speaker illustration

Mr Jeffrey Trocio

New York ()

Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population

Event: ESC CONGRESS 2017

Topic: Atrial fibrillation (AF)

Session: Bleeding and LAA occlusion

Thumbnail

Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation II

Thumbnail

This platform is supported by

logo Novo Nordisk